Evoke Pharma, Inc. Initiates Phase 3 Clinical Trial Of EVK-001 For Treatment Of Gastroparesis
4/22/2014 9:16:44 AM
SOLANA BEACH, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its Phase 3 clinical trial investigating the use of EVK-001, a novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Help employers find you! Check out all the jobs and post your resume.
comments powered by